PALO ALTO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) — Cognoa, a company offering an AI-based platform for pediatric behavioral health diagnostics and digital therapeutics, announces that the U.S. Food and Drug Administration (FDA) has established that Cognoa’s software is a Class II diagnostic medical device for autism. This milestone will
